

Office of Evidence Based Practice (EBP) – Critically Appraised Topic (CAT): Isolation Needs for Patients with extended-spectrum β -lactamase (ESBL)

Specific Care Question

Are criteria necessary to stop contact precautions (CP) in patients diagnosed with ESBL?

Recommendations Based on Current Literature (Best Evidence) Only

A conditional recommendation is made for ceasing the use of contact precautions (CP) for patients diagnosed with ESBL based on expert review of current literature by the Department of EBP. The overall certainty in the evidence is very low^a. The data reported in four studies are incorporated into this report. Based on the study findings, transmission rates of ESBL did not increase significantly after organizations supplanted CP with the use of standard precautions (SP), when caring for patients diagnosed with ESBL.

Literature Summary

Background. ESBL is an enzyme found in some strains of bacteria which have the ability to break down and destroy beta-lactam antibiotics (Centers for Disease Control and Prevention, 2019). ESBL was initially identified as a Hospital Acquired Infection (HAI) due to outbreaks within intensive care units however, the epidemiology has changed to include both HAI and community onset infections (Centers for Disease Control and Prevention, 2019; van Hout et al., 2020). As this disease is spread through the contact of infected human or animal fecal material, hospitalized patients have historically been isolated with CP for each admission after being diagnosed with this disease. However, new literature suggests that patients do not need to be placed in CP. This review will summarize identified literature to answer the specific care question.

In addition to the literature review, an informal city-wide survey ($N = 12$), of the Association for professionals in Infection Control and Epidemiology members (Y. Ballam, personal communication, February 3, 2020), identified that isolation practice is variable when caring for this patient population:

- four organizations isolate with CP for duration of stay,
- three organizations use one or two negative ESBL cultures to determine if CP can be removed,
- two organizations employ CP each time the patient is admitted,
- one organization employs CP for six months from diagnosis,
- one organization uses CP if the patient has an active uncontained infection, and
- one organization does not isolate patients diagnosed with ESBL.

Study characteristics. The search for suitable studies was completed on February 3, 2020. Y. Ballam, BS, CIC; R. Mott, MSN, FNP-BC, CIC, APRN; and S. McCullough-Culer, MPH, BSN, RN, CIC reviewed the 23 titles and/or abstracts^b found in the search. No guidelines were found to answer the question, but nine single studies were believed to answer the question. After an in-depth review of the nine articles^c, four answered the question. All four studies (Jalalzai et al., 2018; Renaudin et al., 2017; Thompson, Teter, & Atrubin, 2020; Tschudin-Sutter et al., 2016) employed a before and after cohort methodology (see Figure 1) to measure the effect of discontinuing CP for patients with a history of ESBL.

Summary by Outcome

Incidence of HAI with ESBL. Four studies (Jalalzai et al., 2018; Marra, Edmond, Schweizer, Ryan, & Diekema, 2018; Renaudin et al., 2017; Thompson et al., 2020; Tschudin-Sutter et al., 2016) reported ESBL transmission in two ways: Incidence rates of health care associated ESBL infection (Jalalzai et al., 2018; Thompson et al., 2020; Tschudin-Sutter et al., 2016) and incidence density rates (Renaudin et al., 2017). The total population for the included studies, nor the reported study findings, could not be pooled due to how the data was reported (a) two studies (Jalalzai et al., 2018; Renaudin et al., 2017) reported the sample size as patients, (b) Tschudin-Sutter et al. (2016) reported only contact and index sample sizes, and (c) Thompson et al. (2020) described the sample size as laboratory specimens.

Jalalzai et al. (2018) reported an insignificant finding ($p = 0.94$) that ICU acquired ESBL infections accounted for 5.2% and 5.5%, before and after, ceasing active surveillance ESBL cultures. Renaudin et al. (2017) reported a significant ($p = .004$) nonsuperiority incidence density finding for ESBL in the ICU before and after ceasing CP 2.7, 95% CI [1.78, 3.62] and 2.06, 95% CI [1.27, 2.86] per 1,000 patient days, respectively. Thompson et al.

Office of Evidence Based Practice (EBP) – Critically Appraised Topic (CAT): Isolation Needs for Patients with extended-spectrum β -lactamase (ESBL)

(2020) described a significant decrease ($p = .022$) when comparing health care-associated ESBL rates before and after eliminating CP 3.71 per 10,000 patient days versus 3.00 per 10,000 patient days, respectively. Tschudin-Sutter et al. (2016) reported a transmission rate of 2.6% after CP were removed for patients with ESBL. These findings indicate that removal of CP in patients diagnosed with ESBL does not significantly ($p = .052$) increase transmission rates when SP are followed.

Certainty of the evidence for HAI with ESBL. The certainty of the body of evidence is based on four factors: within-study risk of bias, consistency among studies, directness of evidence, and precision of effect estimates. The body of evidence was assessed to have very serious risk of bias, and very serious inconsistency. The risk of bias was assessed to be very serious as the four included studies employed a cohort methodology which may have influenced the study findings through uncontrolled confounding variables. The assessment of very serious inconsistency was attributed to the body of literature as different populations and outcome measures were reported.

Identification of Studies

Search Strategy and Results (see Figure 1)

Search: (((("beta-Lactamases"[MeSH] OR "beta-Lactam Resistance"[Mesh]) AND ("Enterobacteriaceae Infections"[Mesh] OR "Enterobacteriaceae"[MeSH])) OR "Drug Resistance, Multiple, Bacterial" [mesh] OR extended-spectrum β -lactamase OR extended-spectrum beta-lactamases OR ESBL-producing E. coli OR ESBL OR extended-spectrum β -lactamase (ESBL) producing organisms OR extended-spectrum β -lactamase) AND (((screen OR screening OR Isolation OR "Transmission-based precautions" OR "contact precautions" OR "infection control" OR effectiveness[tiab]) AND (Cessation OR discontinue OR discontinuation OR discontinue)) OR (Return to Standard Precautions) OR "universal contact precautions")

Records identified through database searching $n = 23$

Studies Included in this Review

Citation	Study Type
Jalalzai et al. (2018)	Before/After cohort
Renaudin et al. (2017)	Before/After cohort
Tschudin-Sutter et al. (2016)	Before/After cohort
Thompson et al. (2020)	Before/After cohort

Studies Not Included in this Review with Exclusion Rationale

Citation	Reason for exclusion
Johnson and Quach (2017)	Narrative review
Marra et al. (2018)	Systematic review which reported the findings from Tschudin-Sutter et al. (2016) as this article is reported as a single study this review was excluded from this report.
Metan et al. (2017)	Letter to the editor
Prevel et al. (2019)	Titled as a systematic review but it was a narrative review
van den Bijllaardt et al. (2018)	Studied the performance of ESBL PCR as a screening assay for ESBL carriage

Methods Used for Appraisal and Synthesis

^a[The GRADEpro Guideline Development Tool \(GDT\)](#) is the tool used grade the overall body of literature for this analysis.

^bRayyan is a web-based software used for the initial screening of titles and / or abstracts for this analysis (Ouzzani, Hammady, Fedorowicz & Elmagarmid, 2017).

^cReview Manager (Higgins & Green, 2011) is a Cochrane Collaborative computer program used to assess the study characteristics as well as the risk of bias and create the forest plots found in this analysis.

**Office of Evidence Based Practice (EBP) – Critically Appraised Topic (CAT):
Isolation Needs for Patients with extended-spectrum β -lactamase (ESBL)**

^dThe Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram depicts the process in which literature is searched, screened, and eligibility criteria is applied (Moher, Liberati, Tetzlaff, & Altman, 2009).

^aGRADEpro GDT: GRADEpro Guideline Development Tool (2015). McMaster University, (developed by Evidence Prime, Inc.). [Software]. Available from gradepro.org.

^bOuzzani, M., Hammady, H., Fedorowicz, Z., & Elmagarmid, A. (2016). Rayyan-a web and mobile app for systematic reviews. *Systematic Reviews*, 5(1), 210. doi:10.1186/s13643-016-0384-4

^cHiggins, J. P. T., & Green, S. e. (2011). *Cochrane Handbook for Systematic Reviews of Interventions [updated March 2011]* (Version 5.1.0 ed.): The Cochrane Collaboration, 2011.

^dMoher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. *PLoS Med* 6(7): e1000097. doi:10.1371/journal.pmed1000097 For more information, visit www.prisma-statement.org.

Question Originator

Bobbi Mott, MSN, FNP-BC, CIC, APRN

Medical Librarian Responsible for the Search Strategy

Keri Swaggart, MLIS, AHIP

EBP Scholar/Team Member Responsible for Analyzing the Literature

Nancy Allen, MS, MLS, RD, LD, CPHQ

Linda Martin, RN, BSN, CPAN

Robyn McCracken, RRT, NPS

Anthony Randall, MHA, RRT, RRT-ACCS, RRT-NPS, C-NPT, CPPS

Kim Robertson, MBA, MT-BC

Ashley Wilson, BSN, RN, CPN

EBP Team Member Responsible for Reviewing, Synthesizing, and Developing this Document

Jacqueline A. Bartlett, PhD, RN

Acronyms Used in this Document

Acronym	Explanation
ASC	Active Surveillance Cultures
CAT	Critically Appraised Topic
CP	Contact Precautions
CRE	Carbapenem-resistant Enterobacteriaceae
EBP	Evidence Based Practice
ESBL	Extended-Spectrum Beta-Lactamase
FPH	Felix Platter Hospital
HAI	Hospital Acquired Infection
ICU	Intensive Care Unit
PRISMA	Preferred Reporting Items for Systematic Reviews and Meta-Analyses
SP	Standard Precautions
UHB	University Hospital Based

Date Developed

April 2020

**Office of Evidence Based Practice (EBP) – Critically Appraised Topic (CAT):
Isolation Needs for Patients with extended-spectrum β -lactamase (ESBL)**




Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)^d

**Office of Evidence Based Practice (EBP) – Critically Appraised Topic (CAT):
Isolation Needs for Patients with extended-spectrum β -lactamase (ESBL)**

Characteristics of Intervention Studies

Jalalzai et al. (2018)

Characteristics of Study	
Methods	Cohort, Pre and Post Intervention
Participants	<p>Participants: Adult patients admitted to the intensive care unit (ICU) during two 1-year periods:</p> <ul style="list-style-type: none"> • Group 1, Pre-intervention, Active surveillance cultures (ASC) timeframe: 4.1.2013 to 3.31.2014 • Group 2, Post-intervention, No active surveillance cultures (no-ASC) timeframe: 9.1.2014 to 8.31.2015 (timeframe began 6 months after ASC cessation) <p>Setting: 18 bed medical-surgical ICU in a teaching hospital in France.</p> <p>Number in study: $N = 1069$</p> <ul style="list-style-type: none"> • Group 1: $n = 524$ • Group 2: $n = 545$ <p>Gender, males: (as defined by researchers)</p> <ul style="list-style-type: none"> • Group 1: $n = 321$ (61.2%) • Group 2: $n = 336$ (61.6%) <p>Race / ethnicity or nationality (as defined by researchers):</p> <ul style="list-style-type: none"> • The study occurred in France. The authors did not identify race or ethnicity of the participants. <p>Age, median in years, IQR</p> <ul style="list-style-type: none"> • Group 1: 65, 54-76 • Group 2: 64, 52-75 <p>Inclusion criteria:</p> <ul style="list-style-type: none"> • Patients with a first ICU stay of more than two calendar days <p>Exclusion criteria:</p> <ul style="list-style-type: none"> • Not reported <p>Covariates identified:</p> <ul style="list-style-type: none"> • Not reported
Interventions	<p>Both:</p> <ul style="list-style-type: none"> • Pre-intervention: Patients routinely screened for ESBL carriage by rectal swabbing at admission then weekly afterwards. • Post-intervention: Policy of systematic screening for ESBL carriage withdrawn.

**Office of Evidence Based Practice (EBP) – Critically Appraised Topic (CAT):
Isolation Needs for Patients with extended-spectrum β -lactamase (ESBL)**

<p>Outcomes</p>	<p>Primary outcomes:</p> <ul style="list-style-type: none"> • Incidence of ICU-acquired ESBL-E infections* <ul style="list-style-type: none"> ○ Imported carriage was defined as a positive rectal swab within the 48 hours following admission ○ Acquired carriage was defined as a positive surveillance swab in patients with a negative admission sample • Overall carbapenem consumption* • Patient outcomes* <p>Secondary outcome:</p> <ul style="list-style-type: none"> • Not reported <p>Safety outcome:</p> <ul style="list-style-type: none"> • Not reported <p>*Outcomes of interest to the CMH CAT development team</p>																																								
<p>Results</p>	<p>Incidence of ICU-acquired ESBL-E infections</p> <ul style="list-style-type: none"> • 863 rectal swabs total for ASC period (admission = 524; weekly surveillance = 339) <ul style="list-style-type: none"> ○ 28 (5.3%) were identified as ESBL-E carriers <ul style="list-style-type: none"> ▪ 17 (3.2%) with imported carriage ▪ 11 (2.1%) with ICU-acquired carriage • The cumulative incidence of ICU-acquired ESBL-E infections did not differ between periods <table border="1" data-bbox="583 699 1829 821"> <thead> <tr> <th></th> <th>ASC period (n = 524)</th> <th>No-ASC period (n = 545)</th> <th>p value</th> </tr> </thead> <tbody> <tr> <td>ESBL-E ICU acquired infections</td> <td>6 (1.1%)</td> <td>8 (1.5%)</td> <td>.64</td> </tr> <tr> <td>Incidence density per 1,000 patients-days</td> <td>1.2 (6/4,823)</td> <td>1.4 (8/5,608)</td> <td>.80</td> </tr> </tbody> </table> <p>Overall carbapenem consumption</p> <ul style="list-style-type: none"> • Overall carbapenem exposure in patients with no ICU-acquired ESBL-E infection decreased between ASC period and no-ASC period (75 versus 62 carbapenem-days per 1000 patients, respectively, $p = .01$) <table border="1" data-bbox="594 938 1850 1179"> <thead> <tr> <th></th> <th>ASC period</th> <th>No-ASC period</th> <th>p value</th> </tr> </thead> <tbody> <tr> <td>All patients</td> <td>81.5 (383/4823)</td> <td>63.3 (355/5608)</td> <td>.03</td> </tr> <tr> <td>No ICU-acquired ESBL-E infection</td> <td></td> <td></td> <td></td> </tr> <tr> <td>• Overall</td> <td>75 (353/4705)</td> <td>61.9 (315/5088)</td> <td>.01</td> </tr> <tr> <td>• No ESBL-E carriage</td> <td>66 (281/4260)</td> <td>--</td> <td>--</td> </tr> <tr> <td>• ESBL-E carriage</td> <td>161.8 (72/445)</td> <td>--</td> <td>--</td> </tr> <tr> <td>ICU-acquired ESBL-E infection</td> <td>339 (40/118)</td> <td>273.1 (142/520)</td> <td>.15</td> </tr> </tbody> </table>		ASC period (n = 524)	No-ASC period (n = 545)	p value	ESBL-E ICU acquired infections	6 (1.1%)	8 (1.5%)	.64	Incidence density per 1,000 patients-days	1.2 (6/4,823)	1.4 (8/5,608)	.80		ASC period	No-ASC period	p value	All patients	81.5 (383/4823)	63.3 (355/5608)	.03	No ICU-acquired ESBL-E infection				• Overall	75 (353/4705)	61.9 (315/5088)	.01	• No ESBL-E carriage	66 (281/4260)	--	--	• ESBL-E carriage	161.8 (72/445)	--	--	ICU-acquired ESBL-E infection	339 (40/118)	273.1 (142/520)	.15
	ASC period (n = 524)	No-ASC period (n = 545)	p value																																						
ESBL-E ICU acquired infections	6 (1.1%)	8 (1.5%)	.64																																						
Incidence density per 1,000 patients-days	1.2 (6/4,823)	1.4 (8/5,608)	.80																																						
	ASC period	No-ASC period	p value																																						
All patients	81.5 (383/4823)	63.3 (355/5608)	.03																																						
No ICU-acquired ESBL-E infection																																									
• Overall	75 (353/4705)	61.9 (315/5088)	.01																																						
• No ESBL-E carriage	66 (281/4260)	--	--																																						
• ESBL-E carriage	161.8 (72/445)	--	--																																						
ICU-acquired ESBL-E infection	339 (40/118)	273.1 (142/520)	.15																																						

**Office of Evidence Based Practice (EBP) – Critically Appraised Topic (CAT):
Isolation Needs for Patients with extended-spectrum β -lactamase (ESBL)**

Patient outcomes

- In-ICU death was similar during the two periods, ICU length of stay, hospital length of stay and hospital mortality rates did not significantly differ.

	All patients <i>n</i> = 1069	ASC period <i>n</i> = 524	No-ASC period <i>n</i> = 545	<i>p</i> value
ICU median length of stay (IQR), days	6 (4-11)	6 (4-11)	6(4-11)	.82
Hospital median length of stay (IQR), days	16 (8-27)	16 (9-27)	16 (8-29)	.89
In-ICU mortality, <i>n</i> (%)	220 (20.6)	101 (19.3)	119 (21.8)	.30
Hospital mortality, <i>n</i> (%)	272 (25.4)	130 (24.8)	142 (26.1)	.64

- The cumulative incidence of ICU-acquired ESBL-E infections did not differ between periods
- Overall carbapenem exposure in patients with no ICU-acquired ESBL-E infection decreased between ASC period and no-ASC period (75 versus 62 carbapenem-days per 1000 patients, respectively, *p* = .01)

**Office of Evidence Based Practice (EBP) – Critically Appraised Topic (CAT):
Isolation Needs for Patients with extended-spectrum β -lactamase (ESBL)**

Renaudin et al. (2017)

<i>Characteristics of Study</i>	
Methods	Cohort, Pre and Post Intervention
Participants	<p>Participants: Adult patients in an ICU before, when contact isolation precautions were in place, and after when SP were in place</p> <p>Setting: An intensive care unit in France</p> <p>Number enrolled into study: $N = 3,124$</p> <ul style="list-style-type: none"> • Group 1, CP: $n = 1,547$ • Group 2, SP: $n = 1,577$ <p>Number completed: $N = 3,124$</p> <ul style="list-style-type: none"> • Group 1, CP: $n = 1,547$ • Group 2, SP: $n = 1,577$ <p>Gender, males: (as defined by researchers)</p> <ul style="list-style-type: none"> • Group 1, CP: $n = 59.5\%$ • Group 2, SP: $n = 60.8\%$ <p>Race / ethnicity or nationality (as defined by researchers):</p> <ul style="list-style-type: none"> • The study occurred in France. The authors did not identify race or ethnicity of the participants. <p>Age, mean, years (SD)</p> <ul style="list-style-type: none"> • Group 1, CP: $n = 65.3 (16.3)$ • Group 2, SP: $n = 62.9 (16.1)$ <p>Inclusion criteria:</p> <ul style="list-style-type: none"> • All patients admitted to the hospital's ICU <ul style="list-style-type: none"> ○ Group 1, CP: January 1, 2012 to January 31, 2014 ○ Group 2, SP: February 1, 2014 to February 29, 2016 <p>Exclusion criteria:</p> <ul style="list-style-type: none"> • There were no exclusion criteria <p>Covariates identified:</p> <ul style="list-style-type: none"> • Hand hygiene compliance • Notification of all patient supporting health care providers of changes of precautions • After Feb 2014 - <ul style="list-style-type: none"> ○ Use of action training, or immediate corrective actions, for all healthcare provider and newcomers on WHO hand hygiene recommendations, ○ Compliance to selection, donning, and doffing PPE per hospital standard

**Office of Evidence Based Practice (EBP) – Critically Appraised Topic (CAT):
Isolation Needs for Patients with extended-spectrum β -lactamase (ESBL)**

<p>Interventions</p>	<p>CP: These were discontinued from February 1, 2014 onward for patients colonized or infected with MRSA or ESBL</p> <ul style="list-style-type: none"> • Hand hygiene on entering and leaving the room • Wear gloves when touching the patient's skin or items in close proximity to the patient • Wear gown if anticipating your clothing will touch the patient's items potentially contaminated surfaces • Use patient-dedicated or single use disposable equipment, or clean and disinfect shared equipment between patients, eg blood pressure cuffs <p>SP:</p> <ul style="list-style-type: none"> • Hand hygiene with alcohol-based hand rub before and after patient/ patient environment contact • Wearing PPE if contact with blood or body fluids was a risk • Notification of all patient supporting health care providers of changes of precautions
<p>Outcomes</p>	<p>Definitions:</p> <ul style="list-style-type: none"> • ICU- acquired case of MRSA or ESBL defined if the first positive culture occurred \geq 48 hours of ICU admission • Carriage at admission if positive culture(s) occurred prior to 48 hours <p>Primary outcome:</p> <ul style="list-style-type: none"> • Incidence density of ICU acquired MRSA or ESBL* per 1,000 patient days <p>Secondary outcomes:</p> <ul style="list-style-type: none"> • Incidence of carriage of MRSA or ESBL at admission • Antibiotic consumption reported quarterly as defined daily dose (DDD)/1,000 patient days • Compliance to hand hygiene protocols - Use of alcohol-based hand-rub reported as liters/1,000 patient days • Compliance to selection, donning, and doffing PPE per hospital standard • Length of stay <p>Safety outcome:</p> <ul style="list-style-type: none"> • Not reported <p>*Outcomes of interest to the CMH CAT development team</p>

**Office of Evidence Based Practice (EBP) – Critically Appraised Topic (CAT):
Isolation Needs for Patients with extended-spectrum β -lactamase (ESBL)**

Results	<p>Statistics: For the incidence density of acquired and carriage MRSA or ESBL the noninferiority analysis was employed. Both were expected to have nonsuperior incidence during the standard precaution period.</p> <ul style="list-style-type: none"> • Incidence densities were compared using Schuirmann's 2 one-sided test (TOST) • Margin of nonsuperiority for both was fixed at one multidrug-resistant organism per 1,000 patient days <p>Results:</p> <ul style="list-style-type: none"> • Acquisition of MRSA in the ICU, incidence density was significantly nonsuperior during the standard precaution with a margin of 1/1,0000 days, $p = .002$ <ul style="list-style-type: none"> ◦ Group 1, CP - 10 patients ◦ Group 2, SP - 10 patients • Acquisition of ESBL-E in the ICU, incidence density was significantly nonsuperior during the standard precaution period with a margin of 1/1,000 patient days, $p = .004$ <ul style="list-style-type: none"> ◦ Group 1, CP - 33 patients ◦ Group 2, SP - 26 patients • Carriage of MRSA at admission, incidence density was significantly noninferior during the standard precaution with a margin of 1/1,000 patient days, $p = .05$ • Carriage of ESLB at admission was not significantly different between periods • There was no significant difference in antibiotic consumption, alcohol-based hand-rub use, compliance to PPE selection and use standards, or length of stay
----------------	---

Thompson et al. (2020)

<i>Characteristics of Study</i>	
Methods	Cohort, Pre and Post Intervention
Participants	<p>Participants: Hospitalized patients with extended-spectrum β-lactamase-positive (ESBL) producing organism Setting: USA, Urban academic 1,010 bed medical center Number of laboratory results during study: $N = 1,273$ (January 2014-August 2017) Gender, males: (as defined by researchers)</p> <ul style="list-style-type: none"> • The study occurred in 2020 in the United States. The authors did not identify gender of the participants. <p>Race / ethnicity or nationality (as defined by researchers):</p> <ul style="list-style-type: none"> • The study occurred in 2020 in the United States. The authors did not identify race or ethnicity of the participants. <p>Age:</p> <ul style="list-style-type: none"> • The study occurred in 2020 in the United States. The authors did not identify age of the participants. <p>Inclusion criteria:</p> <ul style="list-style-type: none"> • Positive laboratory result for ESBL organism <p>Exclusion criteria:</p> <ul style="list-style-type: none"> • <i>Enterobacteriaceae</i> that met definitions for either Carbapenem-resistant Enterobacteriaceae (CRE) or carbapenemase producer-CRE • Surgical site infection <p>Covariates identified:</p> <ul style="list-style-type: none"> • Not reported

**Office of Evidence Based Practice (EBP) – Critically Appraised Topic (CAT):
Isolation Needs for Patients with extended-spectrum β -lactamase (ESBL)**

Interventions	Group 1: CP for ESBL-positive laboratory results Group 2: No CP for ESBL-positive (only) laboratory results																																														
Outcomes	Primary outcome: <ul style="list-style-type: none"> Incidence of healthcare acquired infection (HAI) with ESBL-positive laboratory results* Secondary outcome: <ul style="list-style-type: none"> Number of patients not being placed in CP Safety outcome: <ul style="list-style-type: none"> Not reported *Outcomes of interest to the CMH CAT development team																																														
Results	<ul style="list-style-type: none"> Reported 387 cases of HAI with ESBL infections during the entire study time frame. Pooled ESBL incidence density rate decreased from 3.71 per 10,000 patient days to 3.0 per 10,000 patient days. Documented HAI associated ESBL infection after discontinuation of CP was 25% Lower compared with the baseline period ($p < .001$). The Durbin-Watson statistic confirmed no autocorrelation (Durbin-Watson = 2.11) and the Dickey-Fuller unit root test confirmed stationarity of the outcome variable (tau, -6.54; $p < .001$) for the model. Approximately 378 patients with ESBL-positive organisms were not placed in isolation. <table border="1" data-bbox="583 685 2003 1010"> <thead> <tr> <th rowspan="2"></th> <th colspan="3">Pre-Intervention (January 2014 - November 2015)</th> <th colspan="3">Post-Intervention (December 2015 - August 2017)</th> <th rowspan="2"><i>p</i> value</th> </tr> <tr> <th>Number</th> <th>Denominator</th> <th>Rate</th> <th>Number</th> <th>Denominator</th> <th>Rate</th> </tr> </thead> <tbody> <tr> <td>Community Prevalence Rate (per 10,000 patient encounters)</td> <td>370</td> <td>282,145</td> <td>13.114</td> <td>516</td> <td>299,983</td> <td>17.201</td> <td>.001</td> </tr> <tr> <td>HAI incidence rate [all organisms] (per 10,000 patient days)</td> <td>221</td> <td>595,336</td> <td>3.712</td> <td>166</td> <td>553,748</td> <td>2.998</td> <td><.001</td> </tr> <tr> <td>Community Prevalence Rate (per 10,000 patient encounters)</td> <td>370</td> <td>282,145</td> <td>13.114</td> <td>516</td> <td>299,983</td> <td>17.201</td> <td>.001</td> </tr> <tr> <td>HAI incidence rate [all organisms] (per 10,000 patient days)</td> <td>221</td> <td>595,336</td> <td>3.712</td> <td>166</td> <td>553,748</td> <td>2.998</td> <td><.001</td> </tr> </tbody> </table>		Pre-Intervention (January 2014 - November 2015)			Post-Intervention (December 2015 - August 2017)			<i>p</i> value	Number	Denominator	Rate	Number	Denominator	Rate	Community Prevalence Rate (per 10,000 patient encounters)	370	282,145	13.114	516	299,983	17.201	.001	HAI incidence rate [all organisms] (per 10,000 patient days)	221	595,336	3.712	166	553,748	2.998	<.001	Community Prevalence Rate (per 10,000 patient encounters)	370	282,145	13.114	516	299,983	17.201	.001	HAI incidence rate [all organisms] (per 10,000 patient days)	221	595,336	3.712	166	553,748	2.998	<.001
	Pre-Intervention (January 2014 - November 2015)			Post-Intervention (December 2015 - August 2017)			<i>p</i> value																																								
	Number	Denominator	Rate	Number	Denominator	Rate																																									
Community Prevalence Rate (per 10,000 patient encounters)	370	282,145	13.114	516	299,983	17.201	.001																																								
HAI incidence rate [all organisms] (per 10,000 patient days)	221	595,336	3.712	166	553,748	2.998	<.001																																								
Community Prevalence Rate (per 10,000 patient encounters)	370	282,145	13.114	516	299,983	17.201	.001																																								
HAI incidence rate [all organisms] (per 10,000 patient days)	221	595,336	3.712	166	553,748	2.998	<.001																																								

**Office of Evidence Based Practice (EBP) – Critically Appraised Topic (CAT):
Isolation Needs for Patients with extended-spectrum β -lactamase (ESBL)**

Tschudin-Sutter et al. (2016)

<i>Characteristics of Study</i>	
Methods	Cohort, Pre and Post Intervention
Participants	<p>Participants: Hospitalized patients and long-term care facility patients Setting: University Hospital Basel (UHB) and affiliated long-term care center Felix Platter Hospital (FPH), Basel, Switzerland Number enrolled into study: $N = 442$</p> <ul style="list-style-type: none"> • Group 1, Index Patients: $n = 211$ <ul style="list-style-type: none"> • UHB Patients: $n = 178$ • FPH Patients: $n = 33$ • Group 2, Contact Patients: $n = 231$ <ul style="list-style-type: none"> • UHB Patients: $n = 151$ • FPH Patients: $n = 80$ <p>Number completed: $N = 442$</p> <ul style="list-style-type: none"> • Group 1: $n = 211$ • Group 2: $n = 231$ <p>Gender, males: Not reported Race / ethnicity or nationality (as defined by researchers): <ul style="list-style-type: none"> • The study occurred in Switzerland. The authors did not identify race or ethnicity of the participants. Age: Not reported Inclusion criteria: Not reported Exclusion criteria: Not reported Covariates identified: Not reported</p>
Interventions	<p>Both: UHB and FPH abandoned routine CP for patients with extended-spectrum β-lactamase (ESBL)-producing <i>Escherichia coli</i> (<i>E. coli</i>)</p> <ul style="list-style-type: none"> • Group 1: Patients colonized or infected with an ESBL-producing <i>E. coli</i> • Group 2: Patients hospitalized for at least 24 hours in the same room as an index patient <ul style="list-style-type: none"> ○ Screened for ESBL-producing <i>E. coli</i> after a median contact time of 4 days at UHB and 15 days at FPH

**Office of Evidence Based Practice (EBP) – Critically Appraised Topic (CAT):
Isolation Needs for Patients with extended-spectrum β -lactamase (ESBL)**

<p align="center">Outcomes</p>	<p>Primary outcome:</p> <ul style="list-style-type: none"> • ESBL- producing <i>E. coli</i> transmission rates* <p>Secondary outcome:</p> <ul style="list-style-type: none"> • Contact time* <p>Safety outcome:</p> <ul style="list-style-type: none"> • Not reported <p>*Outcomes of interest to the CMH CAT development team</p>
<p align="center">Results</p>	<ul style="list-style-type: none"> • After discontinuing contact isolation precautions in shared hospital rooms where a patient with ESBL-producing <i>E.coli</i> (index patient) was exposed to a patient without the infection (contact patient) for at least 24 hours, transmission rates were 2.6% and 8.8% at an acute-care (UHB) and a geriatric/rehabilitation hospital (FPH), respectively. • With the use of CP, the reported transmission rates were 1.5% at UHB, and 6.5% for similar settings to FPH (previous transmission rates for FPH specifically were not reported). • Exposure to an index patient for >5 days was associated with increased odds for transmission $OR = 10.18$, 95% CI [1.28, 80.91], $p = .028$

Office of Evidence Based Practice (EBP) – Critically Appraised Topic (CAT): Isolation Needs for Patients with extended-spectrum β -lactamase (ESBL)

References

- Centers for Disease Control and Prevention. (2019). ESBL-producing Enterobacteriaceae in Healthcare Setting. Retrieved from <https://www.cdc.gov/hai/organisms/ESBL.html>
- Jalalzai, W., Boutrot, M., Guinard, J., Guigon, A., Bret, L., Poisson, D. M., . . . Barbier, F. (2018). Cessation of screening for intestinal carriage of extended-spectrum β -lactamase-producing Enterobacteriaceae in a low-endemicity intensive care unit with universal contact precautions. *Clinical Microbiology and Infection*, 24(4), 429.e427-429.e412. doi:<https://doi.org/10.1016/j.cmi.2017.08.005>
- Johnson, J., & Quach, C. J. (2017). Outbreaks in the neonatal ICU: a review of the literature. *Current Opinion in Infectious diseases*, 30(4), 395-403.
- Marra, A. R., Edmond, M. B., Schweizer, M. L., Ryan, G. W., & Diekema, D. J. (2018). Discontinuing contact precautions for multidrug-resistant organisms: a systematic literature review and meta-analysis. *American Journal of Infection Control*, 46(3), 333-340.
- Metan, G., Metin, B. C., Baştuğ, Z., Tekin, İ., Aytaç, H., Çınar, B., Zengin, H., & Unal, S. (2017). Cessation of contact precautions for extended-spectrum beta-lactamase (ESBL)-producing *Escherichia coli* seems to be safe in a nonepidemic setting. *Infection Control & Hospital Epidemiology*, 38(11), 1379-1381.
- Prevel, R., Boyer, A., M'Zali, F., Lasheras, A., Zahar, J.-R., Rogues, A.-M., & Gruson, D. J. (2019). Is systematic fecal carriage screening of extended-spectrum beta-lactamase-producing Enterobacteriaceae still useful in intensive care unit: A systematic review. *Critical Care*, 23(1), 170.
- Renaudin, L., Llorens, M., Goetz, C., Gette, S., Citro, V., Poulain, S., Vanson, M., Sellies, J. (2017). Impact of discontinuing contact precautions for MRSA and ESBL in an intensive care unit: A prospective noninferiority before and after study. *Infection Control & Hospital Epidemiology*, 38(11), 1342-1350.
- Thompson, P., Teter, J., & Atrubin, K. J. A. (2020). Incidence of health care-associated extended-spectrum β -lactamase-positive patients before and after discontinuation of contact precautions. *American Journal of Infection Control*, 48(1), 52-55.
- Tschudin-Sutter, S., Frei, R., Schwahn, F., Tomic, M., Conzelmann, M., Strandén, A., & Widmer, A. F. (2016). Prospective validation of cessation of contact precautions for extended-spectrum β -lactamase-producing *Escherichia coli*. *Emerging Infectious Diseases*, 22(6), 1094.
- van den Bijllaardt, W., Janssens, M., Buiting, A., Muller, A., Mouton, J., & Verweij, J. J. (2018). Extended-spectrum β -lactamase (ESBL) polymerase chain reaction assay on rectal swabs and enrichment broth for detection of ESBL carriage. *Journal of Hospital Infection*, 98(3), 264-269.
- van Hout, D., Verschuuren, T. D., Bruijning-Verhagen, P. C. J., Bosch, T., Schürch, A. C., Willems, R. J. L., Bonten, M. J. M., Kluytmans, J. A. J. W. (2020). Extended-spectrum beta-lactamase (ESBL)-producing and non-ESBL-producing *Escherichia coli* isolates causing bacteremia in The Netherlands (2014 – 2016) differ in clonal distribution, antimicrobial resistance gene and virulence gene content. *PLOS ONE*, 15(1), e0227604. doi:10.1371/journal.pone.0227604